pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
PATH · news · pharmadog
← back to PATH
News mentioning PATH
183
stories
23d
STAT+: American Diabetes Association, facing calls for resignations, asks for patience
stat
23d
FDA staff say Replimune's melanoma trial failed to prove RP1 works
endpoints
24d
STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials
stat
24d
STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment
stat
24d
STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more
stat
24d
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
biospace
24d
The FDA was all in on AI. Will that change?
biopharma dive
24d
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
biospace
24d
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
fiercebiotech
24d
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
fiercebiotech
24d
STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment
stat
24d
MapLight dives despite positive data for schizophrenia drug
biopharma dive
24d
UPDATE: FDA disputes Capricor's claims of Phase 3 success for DMD cell therapy
biospace
24d
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
biospace
24d
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
biospace
24d
MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 win
endpoints
25d
STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
stat
25d
After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
fiercebiotech
25d
Opinion: How midwives like me can help fight medical misinformation
stat
25d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
25d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
27d
Ipsen’s Bylvay fails key trial in children with rare liver disease
endpoints
28d
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
28d
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
endpoints
28d
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
fiercebiotech
28d
Opinion: I may be one of the last middle-class medical students who could afford to become a doctor
stat
28d
Senate health panel delays vote on CDC nominee
stat
29d
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
29d
STAT+: Trump promised redemption for troops who refused Covid shots. A year later, many are still waiting
stat
29d
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
← prev
page 3 of 7
next →
